EDISON EQUITY RESEARCH - CAPSTONE THERAPEUTICS
27 Abril 2015 - 2:46PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: CAPSTONE THERAPEUTICS - FOCUS ON
ACUTE PANCREATITIS
Capstone is investigating a promising new indication for its Apo-E
mimetics triglyceride lowering in acute pancreatitis, an orphan
indication with high unmet medical need and requiring only small,
rapid clinical trials. AEM-28 has demonstrated significant
reductions in VLDL and triglycerides in its Phase I/IIa programme
and development for follow-on AEM-28-02 is underway. However, new
funding will be needed to progress clinical trials.
Capstone Therapeutics’ lead candidate AEM-28 has completed a Phase
I/II clinical trial for orphan disease homozygous familial
hypercholesterolemia. Follow-on AEM-28-02 also has potential in
broader CV indications. Capstone owns 60% of AEM-28 through a JV
with LipimetiX Development..
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports
Capstone Therapeutics (QB) (USOTC:CAPS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Capstone Therapeutics Corporation (QB) (OTCMarkets): 0 recent articles
Más de Capstone Therapeutics Corp (QB) Artículos de Noticias